HM Payson & Co. acquired a new stake in Maximus, Inc. (NYSE:MMS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 6,125 shares of the health services provider’s stock, valued at approximately $448,000.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Globeflex Capital L P lifted its position in shares of Maximus by 0.8% in the fourth quarter. Globeflex Capital L P now owns 23,199 shares of the health services provider’s stock valued at $1,698,000 after buying an additional 179 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in Maximus by 4.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 4,930 shares of the health services provider’s stock worth $361,000 after purchasing an additional 222 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in Maximus by 3.3% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 8,431 shares of the health services provider’s stock worth $617,000 after purchasing an additional 266 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Maximus by 0.4% during the 3rd quarter. California State Teachers Retirement System now owns 94,326 shares of the health services provider’s stock worth $6,453,000 after purchasing an additional 349 shares during the last quarter. Finally, Fieldpoint Private Securities LLC acquired a new stake in Maximus during the 4th quarter worth approximately $32,000. 92.89% of the stock is owned by institutional investors.
In other news, Vice Chairman Richard A. Montoni sold 12,000 shares of Maximus stock in a transaction on Tuesday, March 23rd. The stock was sold at an average price of $87.13, for a total value of $1,045,560.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Vice Chairman Richard A. Montoni sold 11,000 shares of Maximus stock in a transaction on Thursday, March 25th. The shares were sold at an average price of $86.45, for a total value of $950,950.00. The disclosure for this sale can be found here. 2.00% of the stock is owned by insiders.
Maximus (NYSE:MMS) last announced its quarterly earnings data on Thursday, February 4th. The health services provider reported $1.03 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.94 by $0.09. The firm had revenue of $945.60 million during the quarter, compared to analysts’ expectations of $846.46 million. Maximus had a return on equity of 17.60% and a net margin of 6.20%. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.91 EPS. On average, equities analysts expect that Maximus, Inc. will post 3.63 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, February 26th. Shareholders of record on Friday, February 12th were issued a $0.28 dividend. The ex-dividend date was Thursday, February 11th. This represents a $1.12 annualized dividend and a yield of 1.23%. Maximus’s dividend payout ratio is presently 33.04%.
Separately, Raymond James lifted their price target on Maximus from $90.00 to $96.00 and gave the stock a “strong-buy” rating in a report on Friday, February 5th.
Maximus Company Profile
Maximus, Inc provides business process services (BPS) to government health and human services programs worldwide. It operates through three segments: U.S. Services, U.S. Federal Services, and Outside the U.S. The U.S. Services segment offers various BPS solutions, such as program administration, appeals and assessments, and related consulting works for U.S.
Further Reading: What economic reports are most valuable to investors?
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.